A new optotype and chart for precision visometry

Алиев, А-Г. Д.; Алиев, А. А-Г.; Нурудинов, М. М.

doi:10.21516/2072-0076-2019-12-4-8-12

Rossijskij oftalʹmologičeskij žurnal

2019

DOI: 10.21516/2072-0076-2019-12-4-8-12

|View full text |Cite

A new optotype and chart for precision visometry

А-Г. Д. Алиев

А. А-Г. Алиев²,

М. М. Нурудинов³

Abstract: Цель работы -разработка и оценка достоверности нового оптотипа и таблицы для прецизионных визометрических исследований. Материал и методы. Обследовано 56 пациентов в возрасте 16-57 лет. Критерием включения в исследование явилась максимальная острота зрения (ОЗ) 1,0 и более. ОЗ определяли с использованием трех разных оптотипов: стандартных буквенных оптотипов таблицы Сивцева -Головина, колец Ландольта и предлагаемого нами оптотипа. Результаты. На основе психометрического анализа результатов составлены соответст… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Clinical, functional and aberrometric parallels in the treatment of the neovascular form of age-related macular degeneration

Magomedova,

Aliyev,

Zakieva

et al. 2024

Rossijskij oftalʹmologičeskij žurnal

View full text Add to dashboard Cite

Purpose: to analyze clinico-functional and aberrometric parameters of patients with the neovascular form of age–related macular degeneration (nAMD) treated by the anti-VEGF drug brolucizumab. Material and methods. The study involved 59 patients (59 eyes) aged 55 to 75 years, divided into two groups depending on the type of treatment. Group 1 consisted of 25 patients (25 eyes) who had previously received no anti-VEGF therapy and Group 2 had 34 patients (34 eyes) with an active nAMD form, who had previously been given anti-angiogenic therapy with aflibercept. All patients averagely received 5.48±1.5 brolucizumab injections in the “treat and extend” mode: 3 loading injections with monthly checkups followed by elongated intervals reaching 8 weeks. The treatment effectiveness was estimated by the change in maximum corrected visual acuity (MCVA) as measured by precision visometry, the aberrations parameters of the optical system of the eye, and the thickness of the central retinal zone (CRZ). In addition, the height of retinal pigment epithelium (RPE) detachment, the presence of intraretinal fluid (IRF), subretinal fluid (SRF), and fluid under RPE. Results. In group 1, BCVA whose initial value was 0.37 ± 0.16 reached 0.78 ± 0.25 (p = 0.02) by the end of treatment, while in group 2, the value rose from 0.35 ± 0.18 to 0.62 ± 0.22 (p = 0.02). After the 5th injection, Group 1 showed a statistically significant decrease in TCZV (ave. by 270.17 ± 92.37 μm, p=0.05), while Group 2 showed a less pronounced morphological result (a decrease from 480.54 ± 174.22 to 320.32 ± 109.53, p < 0.05). Both groups also showed, after the 5th injection, a decrease in the cumulative frequency of occurrence of various types of fluid (p < 0.02). A decrease in all components of higher order aberrations was also noted after the first 3 injections; this result remained stable until the end of the observation period (p = 0.04). Conclusion. In Group 1 patients, we succeeded in achieving high morphological and functional results and maintaining them at a stable level until the end of the observation period. Group 2, patients with an active nAMD, previously treated with other anti-VEGF preparations, showed a less pronounced, though stable improvement in morphofunctional parameters.

show abstract

Clinical, functional and aberrometric parallels in the treatment of the neovascular form of age-related macular degeneration

Magomedova,

Aliyev,

Zakieva

et al. 2024

Rossijskij oftalʹmologičeskij žurnal

View full text Add to dashboard Cite

show abstract

The influence of test illuminance on visual acuity in patients with primary open-angle glaucoma and age-related macular degeneration

Teuvazhukova,

Arutyunyan,

Tlupova

2024

Glaucoma

View full text Add to dashboard Cite

PURPOSE. To study the influence of the illuminance level of test objects on the resolution of the visual analyzer in patients with primary open-angle glaucoma (POAG) and age-related macular degeneration (AMD), and assess the possibility of using the obtained results for early diagnosis of these eye diseases.METHODS. Visual acuity (VA) under controlled illumination conditions (from 50 to 400 lx) of test objects was assessed using the developed device in three groups: in 50 healthy subjects aged 37.08±10.19 years without ophthalmic pathology (group A), in 50 patients with early (Ia and IIa) stages of POAG aged 47.16±8.28 years (group B) and 50 patients aged 46.08±4.56 years (group C) with dry form of AMD (initial stage).RESULTS. With an increase in the illumination of test objects (IT) from 50 to 400 lx, the VA of healthy individuals significantly increases on average by δ=0.32 (from 1.0±0.22 to 1.32±0.24, p<0.01), while in POAG the increase in VA with an increase in IT is much less pronounced, averaging δ=0.12 (from 0.9±0.20 to 1.02±0.26, p<0.05). At the same time, starting from IT 150 lx and above, the differences between the values of VA in the control group and in the group of patients with POAG of the initial stages become significant (p<0.05). VA of patients with AMD with increasing IT practically does not change, remaining at a stable level: δ=0.04 (from 0.76±0.20 to 0.80±0.26, t=0.66, p>0.5). At the same time, the VA values in this group of patients for each illumination level are significantly lower (p<0.05) than the corresponding VA values in the control group (group A).CONCLUSION. The revealed regularities can be used for early diagnosis of the pathological process: an increase in VA at the maximum level of IT relative to the initial value by less than δ≤0.2 indicates pathology of the optic nerve (POAG), and the absence of significant changes in VA with an increase in IT (minimum values of δ) is characteristic of the pathological process in the macula (AMD).

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A new optotype and chart for precision visometry

Cited by 2 publications

References 14 publications

Clinical, functional and aberrometric parallels in the treatment of the neovascular form of age-related macular degeneration

Clinical, functional and aberrometric parallels in the treatment of the neovascular form of age-related macular degeneration

The influence of test illuminance on visual acuity in patients with primary open-angle glaucoma and age-related macular degeneration

Contact Info

Product

Resources

About